Efficacy of combination therapy of lamivudine and adefovir dipivoxyl for patients with hepatitis B-induced decompensated liver cirrhosis.
10.3969/j.issn.1672-7347.2012.12.016
- Author:
Jing YANG
1
,
2
;
Xuan ZHU
;
He WANG
Author Information
1. Department of Gastroenterology, People's Hospital of Yichun City, Yichun Jiangxi, China. jyyfyzx@
2. com
- Publication Type:Journal Article
- MeSH:
Adenine;
administration & dosage;
analogs & derivatives;
Adult;
Antiviral Agents;
therapeutic use;
Drug Therapy, Combination;
End Stage Liver Disease;
drug therapy;
etiology;
Female;
Hepatitis B, Chronic;
complications;
Humans;
Lamivudine;
administration & dosage;
Liver Cirrhosis;
drug therapy;
etiology;
physiopathology;
Male;
Middle Aged;
Organophosphonates;
administration & dosage
- From:
Journal of Central South University(Medical Sciences)
2012;37(12):1269-1273
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the efficacy of combination therapy of lamivudine (LAM) and adefovir dipivoxyl (ADV) for patients with hepatitis B-induced decompensated cirrhosis.
METHODS:A total of 81 patients were randomly divided into a combination group and an ADV group over 48 week treatment course. The combination group were treated with LAM (100 mg/d) plus ADV (10 mg/d), and the ADV group with ADV (10 mg/d ) for 48 weeks. All patients received hepatic function support and symptomatic treatment. The levels of HBV DNA, liver function, Child-Pugh scores and HBV DNA indicators were observed before and after the treatment.
RESULTS:At week 4, the mean reduction of HBV DNA was 1.83 lgIU/mL, 17.9% of the patients achieved undetectable HBV DNA and 28.2% showed normal ALT in the combination group. The counterpart in the ADV group was 0.96 lgIU/mL, 5.3% and 10.5%. At week 4, 12, 24 and 48, the differences in the mean reduction of HBV DNA, undetectable HBV DNA and ALT normalization were statistically significant between the 2 groups. The difference in HBeAg negative conversion rates and HBeAg seroconversion at week 24 and 48 was not significant.
CONCLUSION:The combination therapy results in HBV suppression and improved liver function and Child-Pugh score. The combination treatment has an advantage over ADV due to low drug resistance rate and good tolerance.
